ArticleAdvances in therapy2025
Identifying Treatable Traits of Patients with Asthma Prescribed an ICS/LABA: A Descriptive Analytic Database Study in England.
Article in Advances in therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Inhaled Corticosteroid/Long-Acting βAdvances in therapy · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
introductionWe aimed to understand predictors of moderate-to-severe asthma exacerbations and high short-acting β
methodsThis non-interventional, longitudinal, retrospective study used medical record data (Clinical Practice Research Datalink Aurum; Hospital Episode Statistics) in England. Eligible patients with diagnosed asthma were ≥ 18 years old 12 months before the first observed single-inhaler twice-daily ICS/LABA prescription date (December 1, 2017-March 31, 2019). Patients were stratified by occurrence of moderate-to-severe exacerbation and SABA use during 12 months' follow-up. Study outcomes included exacerbation occurrence and SABA use. Latent class cluster (LCC) analysis distinguished clusters of predictors with high importance (≥ 0.70) identified from random forest analysis and confirmed on clinical relevance. Treatment characteristics were described within each cluster.
resultsMost of 23,567 patients meeting study criteria (80.4%) were white and female (60.3%); mean index age was 50.0 years. Overall, 21 variables were distinguished as key predictors of moderate-to-severe exacerbation (top predictors: comorbid cardiac disease, diabetes, depression, smoking, body mass index [BMI]) and 22 as key predictors of high SABA use (top predictors: comorbid upper respiratory tract infection, cardiac disease, prior SABA use, age, sex). Five clusters each were observed among patients who experienced an exacerbation and those who did not. Among patients with high or lower SABA use, five and six clusters were observed, respectively. Treatment characteristics were similar across clusters. DISCUSSION: This study distinguished treatable and non-treatable predictors of exacerbation and high SABA use. Distinct asthma phenotypes were detected via LCC analysis. Distinguished treatable traits including comorbidities, smoking status and BMI, may be targeted by healthcare professionals.
conclusionOur findings reinforce the importance of personalized asthma treatments with the goal of improving clinical outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.